UPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating cervical cancer patients whose disease had progressed on or after chemotherapy, the agency said on Monday. The treatment, Tivdak - an antibody-drug conjugate co-developed by Genmab A/S and Seagen - received the FDA's accelerated approval for the same indication in 2021. It was added to Pfizer's oncology portfolio last year through a $43 billion deal to acquire Seagen, along with other targeted cancer therapies. The health regulator's full approval was based on data from a late-stage trial that enrolled 502 patients. It tested Tivdak versus investigators' choice of chemotherapy in patients with cervical cancer. Tivdak in the trial demonstrated a 30% reduction in the risk of death in patients, compared with chemotherapy. (Reporting by Pratik Jain in Bengaluru; Editing by Anil D'Silva)
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- 3M Is a Fallen ‘Dividend Aristocrat.' Here's Its New Payout. [Yahoo! Finance]Yahoo! Finance
- AI Program Aims to Break Barriers for Female Students [The New York Times]The New York Times
- 3 No-Brainer Stocks to Buy With $500 Right Now [Yahoo! Finance]Yahoo! Finance
- Merck KGaA's Q1 adjusted profit declines less than feared [Reuters]Reuters
- 2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/9/24 - Form S-8
- 5/8/24 - Form 10-Q
- 5/1/24 - Form 4
- PFE's page on the SEC website